Symphogen, Merck KGaA deal

Symphogen received an undisclosed milestone payment from Merck under a September 2012 deal granting Merck exclusive, worldwide rights to develop and commercialize cancer product Sym004. The payment was triggered by an undisclosed drug development milestone for the product. Merck presented Phase II data for Sym004 in squamous cell carcinoma of the head and neck (SCCHN) and additional Phase I/II data in patients with metastatic colorectal cancer (mCRC) at the American Society of Clinical Oncology meeting in Chicago. Symphogen declined to disclose details, while Merck could not be reached (see BioCentury, Sept. 10, 2012 & June 24, 2013). ...